Table 1
Primers for real-time PCR.

Gene	Forward Primer	Reverse Primer	Product size (bp)
SLC7A11	TGGAGGTCTTTGGTCCCTTG	TAGCGTCCAAAAGCCAGGGA	105
18S rRNA	GACTCAACACGGGAAACCTC	AGACAAATCGCTCCACCAAC	120

SLC7A11: solute carrier family 7 member 11.



Fig. 1. Changes in the protein levels of MALT1, Nrf2 and SLC7A11 in myocardial I/R injury model in vivo or in vitro. A. Infarct size (expressed as percentage of the area at risk). B. Serum creatine kinase (CK) activity. C. Representative images of HE staining for rat cardiac tissues. D-F. Top: optical density for Western blots of MALT1, Nrf2 and SLC7A11 against GAPDH, which were further normalized by the control; bottom, representative images of Western blots for proteins from the rat hearts. G. LDH release from the cultured H9c2 cells. H-J. Top: optical density for Western blots of MALT1, Nrf2 and SLC7A11 against GAPDH, which were further normalized by the control; bottom, representative images of Western blots for proteins from the cultured H9c2 cells. All values were presented as mean ± S.E.M., n = 5–6 per group. I/R: Ischemia/Reperfusion; H/R: Hypoxia/Reoxygenation. $^{**}P < 0.01$ vs. Sham (in vivo study) or; $^{**}P < 0.01$ vs. Control (in vitro study).